Evidence map›Paper›PMID 35677534›Full record

ArticleOncotarget2022

Are anaplastic lymphoma kinase (ALK) and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation driver biomarkers of pulmonary neuroendocrine tumors (NETs) and carcinomas (NECs)?

Birgitta Hiddinga, Karen Zwaenepoel, Annelies Janssens, Jan Van Meerbeeck, Patrick Pauwels

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Birgitta HiddingaDepartment of Pulmonary Diseases, University Medical Center Groningen, Groningen, The Netherlands.
Karen ZwaenepoelDepartment of Pathology, Antwerp University Hospital, Edegem, Belgium.
Annelies JanssensDepartment of Pulmonology and Thoracic Oncology, European Reference Network for Rare or Low Prevalence Lung Diseases: ERN-LUNG, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
Jan Van MeerbeeckDepartment of Pulmonology and Thoracic Oncology, European Reference Network for Rare or Low Prevalence Lung Diseases: ERN-LUNG, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
Patrick PauwelsDepartment of Pathology, Antwerp University Hospital, Edegem, Belgium.
Antwerp University Hospital · BEUniversity Medical Center Groningen · NLUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel targets in neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) are needed to improve outcome. The presence of O6-Methylguanine-DNA methyltransferase (MGMT) promoter methylation in NETs and NECs may act as a predictive marker for response on treatment with temozolomide. As anaplastic lymphoma kinase (ALK) plays an important role in the nervous system we hypothesized that ALK rearrangement can act as a biomarker in patients with NETs and NECs. MATERIALS AND

methodsWe performed a retrospective analysis to establish the frequency of MGMT promoter methylation and ALK expression in tissue samples of patients with NETs and NECs.

results21% (14/67) of patients tested positive for MGMT promoter methylation. MGMT promoter methylation was present in 33% (3/9) patients with typical carcinoid, in 22% (2/9) patients with atypical carcinoid, in 22% (8/37) patients with small cell lung cancer and in 8% (1/12) patient with large cell neuroendocrine carcinoma. ALK- expression was present in 14% (10 of 70 patients). In all of these patients, no ALK-rearrangement nor ALK-mutation was revealed.

conclusionsRoutine testing of NET and NEC samples for an ALK rearrangement is not recommended as ALK-expression is not associated with an ALK-rearrangement. Routine testing of NET and NEC samples for MGMT will detect a promoter hypermethylation in a sizable minority of patients who are eligible for a targeted treatment with temozolomide.

Indexed as

Carcinoid TumorCarcinoma, NeuroendocrineLung NeoplasmsNeuroendocrine TumorsAnaplastic Lymphoma KinaseBiomarkersDNADNA MethylationDNA Modification MethylasesDNA Repair EnzymesGuanineHumansO(6)-Methylguanine-DNA MethyltransferaseRetrospective StudiesTemozolomideTumor Suppressor ProteinsAnaplastic Lymphoma KinaseBiomarkersDNADNA Modification MethylasesDNA Repair EnzymesGuanineMGMT protein, humanO-(6)-methylguanineO(6)-Methylguanine-DNA MethyltransferaseTemozolomideTumor Suppressor Proteinsanaplastic lymphoma kinaseMGMT promoter methylationneuroendocrine carcinomaneuroendocrine tumorsmall cell lung cancer

Identifiers

PMID35677534
PMCPMC9159705
OpenAlexW4281692084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.